Objective To explore the efficacy ofbevacizumab in patientswithstage III non-small cell lung cancer (NSCLC) and itseffect on the expression of vascular endothelial growth factor (VEGF), matrix metalloproteinase 9 (MMP 9) and cyclooxygenase-2 (COX-2). Methods The clinical data of 95 patients with stage III NSCLCadmitted to Anhui No.2 Provincial People's Hospital from January 2017 to December 2019 were retrospectivelyanalysed.The patients were divided into the combined group (47 cases) and the chemotherapy group (48 cases) by random number table. The chemotherapy group was treated with conventional chemotherapy and the combination group was treated with bevacizumab on the basis of conventional chemotherapy. The two groups were compared in terms of clinical efficacy, serum VEGF, MMP-9 and COX-2 levels before and after treatment, and toxic and side effects(including gastrointestinal reactions, neurotoxicity, hemotoxicity, hand-foot syndrome and hypertension, etc.). Results The overall effective rate of symptom relief in combined group was 85.11%, higher than that of chemotherapy group (62.50%), and the difference was statistically significant (χ2=6.259, P=0.012). The differencein serum VEGF, MMP-9 and COX-2 levels before and after treatment in combination groupwas higher than thatin chemotherapy group, and the differences were statistically significant(t=121.293, 55.989,23.538; allP<0.05). There was no statistically significant difference in the incidence of gastrointestinal reactions, neurotoxicity, hemotoxicity, hand-foot syndrome and hypertension between the two groups (all P>0.05).Conclusions The treatment ofbeacizumab in stage III NSCLC patients has better curative effectand can effectively lower VEGF, MMP-9 and COX-2 levels with highsecurity, thus it is worth clinical popularization and application. |